Invention Grant
- Patent Title: Optimization of enzyme replacement therapy for treatment of homocystinuria
-
Application No.: US16605918Application Date: 2018-04-17
-
Publication No.: US11324811B2Publication Date: 2022-05-10
- Inventor: Tomas Majtan , Jan P. Kraus , Erez M. Bublil , Frank Glavin , Marcia Sellos-Moura
- Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE , Travere Therapeutics Switzerland GmbH
- Applicant Address: US CO Denver; CH Rapperswil-Jona
- Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE,Travere Therapeutics Switzerland GmbH
- Current Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE,Travere Therapeutics Switzerland GmbH
- Current Assignee Address: US CO Denver; CH Rapperswil-Jona
- Agency: Seed Intellectual Property Group LLP
- International Application: PCT/US2018/027854 WO 20180417
- International Announcement: WO2018/195006 WO 20181025
- Main IPC: A61K38/51
- IPC: A61K38/51 ; A61K47/60 ; C12N9/88

Abstract:
The present invention provides a method of PEGylating a human truncated cystathionine β-synthase protein containing a mutation of a cysteine to a serine at amino acid position 15 (htCBS C15S). The htCBS C15S was PEGylated with one of 5 kDa, 10 kDa, or 20 kDa NHS ester PEG molecules. In-process monitoring of the PEGylation process was used in the method to reduce levels of unPEGylated htCBS C15S and htCBS C15S with insufficient PEGylation. Administration of the PEGylated htCBS C15S had efficacy throughout the course of treatment for homocystinuria.
Public/Granted literature
- US20200261555A1 OPTIMIZATION OF ENZYME REPLACEMENT THERAPY FOR TREATMENT OF HOMOCYSTINURIA Public/Granted day:2020-08-20
Information query
IPC分类: